Guanethidine for Pulmonary Hypertension with Heart Failure with a Preserved Ejection Fraction [PH-HFpEF] (ACTRN12625000817448)

Guanethidine for PH-HFpEF

This trial is Currently recruiting
Registration number ACTRN12625000817448
This study will help the researchers understand if guanethidine, a drug used to treat hypertension, is safe and effective in patients with PH-HFpEF.

Program & service

This trial is being run with the Heart & Lung service, and as part of the Cardiology program.

Trial phase

Phase 1

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof David Kaye

Key inclusion data

Inclusion criteria: Age appropriate patient with chronic heart failure; Ongoing stable medical therapy for heart failure; LVEF>= 45% in the past 6months; Suitable heamodynamica measurements; Ability to complete walking tests. Exclusion Criteria: Orthostatic hypotension, Unstable cardiovascular diseases or advanced heart failure; Other unstable medical conditions.

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.